Anupam Rasayan India Ltd., one of India’s leading custom synthesis and specialty chemical players, has announced its financial results for the quarter and half year ended September 30, 2024. The company has posted Q2 FY25 consolidated Profit After Tax at Rs. 30.6 crore as compared to Rs. 48.7 crore in Q2 FY24.

Total revenue for Q2 FY25 was at Rs. 295.9 crore as compared to Rs. 395.6 crore in Q2FY24. EBITDA (incl. other income) was at Rs. 82.4 crore in Q2 FY25 as compared to Rs. 110.9 crore in Q2 FY24, translating into 28 per cent EBITDA margin in this quarter.

For H1 FY25, Anupam Rasayan India has posted PAT of Rs. 42.8 crore as compared to Rs. 100.9 crore in H1 FY24.  Total revenue for H1FY25 was at Rs. 556.2 crore as compared to Rs. 794.4 crore in H1FY24. EBITDA (incl. other income) was at Rs. 141.6 crore in H1 FY25 as compared to Rs. 224.7 crore in H1FY24, translating into a 25 per cent EBITDA margin in H1FY25.

Speaking on the performance, Anand Desai, Managing Director, Anupam Rasayan commented, "In Q2FY25, we were nearing the end of a demand slump in the Agro segment, and we are now seeing a good recovery. The Pharma and Polymer segments, meanwhile, have been showing robust growth, fuelled by the launch of over 17 new molecules in FY24 and 3 additional molecules in H1FY25. As these products gain traction, we expect their contribution to grow. Additionally, the planned launch of more than 3 new molecules in the coming months should further accelerate growth in these areas.

“Our consolidated operating revenue for the quarter was Rs. 294 crore, representing a QoQ growth of 14%, with a stable EBITDA margin of 28% in Q2FY25. We anticipate revenue to normalize as volumes increase in the latter half of the year. With the new capacity, scaling of recently launched fluorinated molecules, and signed LOIs and contracts, we are optimistic about strong growth over the medium term."